New Preclinical Research Presented at AACR 2019 Reveals Unique Anti-Cancer Mechanism of Action Underscoring IMV’s Immunothe...
April 03 2019 - 8:00AM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology corporation, today announced that preclinical
research presented at the American Association for Cancer Research
(AACR) Annual Meeting 2019 demonstrated how the mechanism of action
(MOA) of IMV’s proprietary DPX technology can enhance a broad
spectrum of immune cell infiltration into tumors, which included T
cells, Natural Killer (NK) cells, and macrophages. Analyses also
revealed the differentiated characteristics of the immune cell
responses and the potential implications for enhanced anti-tumor
efficacy.
“The new preclinical data shared at this year’s AACR Annual
Meeting provides greater insight into the unique mechanism of our
immunotherapy programs,” said Marianne Stanford, Vice President,
Research at IMV. “These data demonstrate our commitment to fully
understanding how our platform impacts our product candidates,
which in turn informs our clinical program designs and ability to
identify patient needs that are more likely to benefit from our
approach.”
In the poster titled, T-distributed stochastic neighbor
embedding (t-SNE) analysis of tumor infiltrating lymphocytes after
treatment with a T cell activating therapy identifies a unique
population of recruited CD8+ T cells and novel options for
combination immunotherapy, IMV researchers used specialized data
analytics to examine how DPX-based agents, when combined with
cyclophosphamide (CPA), induced T cells to infiltrate tumors and
attack cancerous cells. The study closely examined the types of
immune cell responses and how and why they were able to affect
disease.
The data indicated that this approach stimulated the
infiltration of a broad base of immune cells into tumors, including
T cells, NK cells, and macrophages. The specific T cell population
that moved into tumors could be grouped based on the co-expression
of different checkpoint molecules such as PD-1 and Tim-3. However,
those stimulated to infiltrate tumors generally did not express
CTLA-4 (a protein found on T cells that inhibits the immune
response).
Researchers also found that combining DPX/CPA treatments with a
CTLA-4-blocking antibody increased efficacy in controlling tumor
growth in the animal models. The data suggested that this result
was due to the antibodies acting on T cells present in the tumors,
rather than those induced by treatment. This finding contrasts
previously published studies with anti-PD-1 combinations in which
treatment directly enhanced DPX-induced T cell responses.
“We believe there is a need for more targeted immunotherapy
approaches and this work is another important step for us toward
achieving this goal,” said Frederic Ors, Chief Executive Officer,
at IMV. “This is a new frontier in immuno-oncology drug
development, and I’m proud of the work our team has done and the
potential it represents to, ultimately, improve treatments for
patients.”
IMV’s current clinical program includes multiple phase 2 studies
assessing the safety and efficacy of its lead candidate,
DPX-Survivac, in combination with mCPA and Merck’s checkpoint
inhibitor, Keytruda®.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory
approval of DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190403005068/en/
MEDIAAndrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.comINVESTOR RELATIONSMarc
Jasmin, IMV Senior Director, Investor Relations and
CommunicationsO: (902) 492-1819 ext: 1042M: (514) 917-9481
E: mjasmin@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024